A5086323374- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- Galectins and Cancer Biology
- Cancer Genomics and Diagnostics
- Genomics and Chromatin Dynamics
- Immunodeficiency and Autoimmune Disorders
- Protein Degradation and Inhibitors
- RNA modifications and cancer
Heidelberg University
2019-2022
European Molecular Biology Organization
2019-2022
University Hospital Heidelberg
2019-2022
European Molecular Biology Laboratory
2019
Transcription factors (TFs) regulate many cellular processes and can therefore serve as readouts of the signaling regulatory state. Yet for TFs, mode action—repressing or activating transcription target genes—is unclear. Here, we present diffTF (https://git.embl.de/grp-zaugg/diffTF) to calculate differential TF activity (basic mode) classify TFs into putative transcriptional activators repressors (classification mode). In basic mode, it combines genome-wide chromatin accessibility/activity...
Abstract The tumour microenvironment and genetic alterations collectively influence drug efficacy in cancer, but current evidence is limited to small scale studies systematic analyses are lacking. We chose Chronic Lymphocytic Leukaemia (CLL), the most common leukaemia adults, as a model disease study this complex interplay systematically. performed combinatorial assay using 12 drugs individually co-applied with each of 17 microenvironmental stimuli 192 primary CLL samples, generating...